The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.
In Science this week: comprehensive cellular map of the human thymus, evidence of admixture between the ancestors of Neanderthals and Denisovan and a 'superarchaic' population.
Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.
The single-cell analysis and spatial genomics company reported $75.3 million in Q4 revenues. Full year revenues grew 68 percent to $245.9 million.
10x Genomics sued Harvard University and 1CellBio, a competing single-cell technology firm, in 2018 over licenses for patents granted to both companies.
Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.
Illumina said the NextSeq 2000 and NextSeq 1000 reduce run costs by up to 50 percent, compared to the NextSeq 550 model, while increasing the data output.
On the second day of the conference, updates came not just from the publicly traded industry giants but also privately held firms of interest, such as Caris and GenapSys.
TC agreed with a judge who said that 10x's older GEM microfluidic chips infringed Bio-Rad patents, but that the firm's new Next GEM chips did not.
The partners will combine the capabilities of S2's Singulator instrument for solid tissue preparation and Dolomite Bio's Nadia single-cell sample prep platform.
The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.
The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.
A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.
In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.